Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Can asciminib reshape first-line CML treatment? Inside Scemblix’s rise as a new standard of care in Canada More than a month after Health Canada’s approval, Scemblix is forcing a rethink of chronic myeloid leukemia therapy—and raising the bar for tolerability and precision. byPallavi MadhirajuAugust 31, 2025